Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Company announcement – No. 26 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, December 19, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology transforming the future of metabolic health, has received information on transactions in Zealand Phar...
Yesterday, Zealand Pharma hosted a CMD outlining its ambition to become a generational metabolic health company. The company highlighted key programs survodutide and petrelintide, and outlined plans to build a broader amylin franchise with plans for oral small molecule enabled by its newly announced collaboration with OTR therapeutics, as well as longer acting monthly amylin products. Zealand aims for five product launches in the next five years, and 10+ clinical pipeline programs by 2030. The c...
Zealand Pharma increases its share capital as a result of the exercise of employee warrants Company announcement – No. 25 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, December 11, 2025 – Zealand Pharma A/S (“Zealand Pharma”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78),), a biotechnology company transforming the future of metabolic health, has by decision of the Board of Directors increased its share capital by a nominal amount of DKK 150,317 divided into 150,317 new shares with a nominal value of DKK 1 each. The capital i...
Zealand will host a CMD this afternoon to outline its Metabolic Frontier 2030 strategy to become a generational biotech leader in metabolic health. The company targets 5 launches, and 10+ clinical pipeline programs by 2030. In addition, the company announced a collaboration agreement with OTR therapeutics for the discovery of small molecule metabolic targets. We are encouraged by the clear targets and partnership with OTR therapeutics, demonstrating Zealand is willing to go beyond its usual area...
Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health Press release – No. 19 / 2025 Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health Zealand Pharma targets five launches, +10 clinical pipeline programs, and industry-leading cycle times from idea to clinic by 2030Catalyst-rich 2026 with multiple clinical readouts, including Phase 2 data with petrelintide in Q1 2026 and Phase 3 obesity data with survodutide throughout 2026New research si...
Zealand Pharma and OTR Therapeutics enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases Press release – No. 18 / 2025 Zealand Pharma and OTR Therapeutics enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases Collaboration will combine Zealand Pharma’s expertise in obesity and metabolic health with OTR Therapeutics’ proprietary oral small-molecule platform and strong drug discovery capabilities, to discover and develop novel therapeutics for multiple targets...
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Company announcement – No. 24 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, December 5, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received i...
HEADLINES: • Optima Bank: buying the dip (stays BUY) • CTP: great story, fairly valued (downgraded to HOLD) • PCF Group: key takeaways from the 3Q25 earnings call • Cyfrowy Polsat/Wirtualna Polska: CPS audience share at 22.37%, while WP TV at 0.46% in November 2025 NEUTRAL • Budimex: plans to pay out 100% of net income in dividends in 2025-29E NEUTRAL • 11 bit studios: finalises agreement with Microsoft on licence for Game Pass POSITIVE • Huuuge Games: October Sensor Tower bookings estimate flat...
We continue to see CTP as one of the best stories in European real estate. A simple, focused investment case, a quality portfolio, value-accretive growth, well-managed. CTP builds at a c.10% yield on cost, while it raises debt at an all-in cost of c.4%, and it books its portfolio on a 5-6% net initial yield. The revaluation gains on developments allow almost all of the construction capex to be debt-funded. The spread between the development yield and the cost of debt is wide, and would remain at...
EME Equity Market – November 2025 Czech PX leads in November, Türkiye the only loser. The MSCI EM Europe Index added 1.5% mom in EUR terms and 2.1% mom in USD terms in November. The Czech PX was the top performer, adding 4.7% mom in EUR terms, followed by the Greek ASE and the Hungarian BUX (+4.4% and +3.7% mom, respectively, in EUR terms). The Romanian BET and Polish WIG 20 were also in the green (+1.3% and +1.0% mom in EUR terms). The only loser was the Turkish ISE 30 (-2.0% mom in EUR terms).
REMINDER: Zealand Pharma’s Capital Markets Day on December 11, 2025 Press release – No. 17 / 2025 REMINDER: Zealand Pharma’s Capital Markets Day on December 11, 2025 Copenhagen, Denmark, December 1, 2025 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, is hosting a Capital Markets Day in London on December 11, 2025, featuring presentations from management and external experts in obesity and metabolism. Time: December 11, 2025, from 1.00-5.30pm GMT (2.00-6.30pm CET)Venue: Goldman...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.